© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
All News
Researchers discover glaucoma and chronic kidney disease have more in common than what meets the eye
June 25, 2022
A team of investigators from the Yong Loo Lin School of Medicine at the National University of Singapore has found that there is a bidirectional association between chronic kidney disease and glaucoma.
Blog: I’ll be Leonardo and so much more
June 25, 2022
In a profession that values super subspecialization, combined with a society that pigeonholes physicians into corners, I often felt I didn’t fit into one job title with my varied passions and cross interests.
RegeneRx licensee to expand Phase 3 clinical trial program with RGN-259
June 24, 2022
RegeneRx Biopharmaceuticals Inc. said its U.S. joint venture partner and licensee, HLB Therapeutics, will expand its ophthalmic clinical development program with RGN-259 in two indications, neurotrophic keratopathy and dry eye disease.
Eyes a haven for Ebola and other viruses
June 24, 2022
A team of investigators at Flinders University in Australia have found that a specific cell within the retina appears to be particularly good at housing Ebola and other viruses.
How quality vision builds a foundation for safety and everyday activities
June 22, 2022
As ophthalmologists observe Cataract Awareness Month this June, William L. Soscia, MD, medical director at Center for Sight, in Sarasota, Florida, focuses on the importance of having excellent vision for safety and everyday functions.
Bausch + Lomb receives permanent J-Code for triamcinolone acetonide injectable suspension
June 21, 2022
The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only therapy available in the United States for suprachoroidal use in the treatment of macular edema associated with uveitis.
A new hope for a therapy against retinitis pigmentosa
June 21, 2022
A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.
Foundation Fighting Blindness announces leadership changes
June 21, 2022
Jason Menzo is named CEO, while Russell Kelley, PhD, MBA, will become managing director of the RD Fund. Ben Yerxa, PhD, will take the helm of Opus Genetics, the first RD Fund- and foundation-backed spin-off company.
Eyelid ptosis case treated with brimonidine 0.33% gel
June 20, 2022
Researchers believe this may be the first report of the use of topical brimonidine gel for the treatment of eyelid ptosis associated with cosmetic use of botulinum toxin.